Psychiatrist.comCatatonia as a Case Study in Psychiatric Decision-Making

🎓 Expert Commentary / Peer Perspective

Catatonia affects nearly 10% of psychiatric inpatients and carries 10-50% mortality in malignant or untreated cases. The authors argue clinical underrecognition warrants a shift toward reflexive empiric treatment when catatonia features appear on the differential.

Professional Impact

• Authors classify catatonia as a “green” condition in their proposed matrix — high morbidity paired with effective, well-tolerated treatment, warranting empiric action over diagnostic delay.
• The lorazepam challenge functions as both diagnostic and therapeutic, reducing the cost of treating when uncertainty remains.
• Undertreatment drivers cited include clinician discomfort with high benzodiazepine doses, ECT unavailability, and overlap with delirium, psychosis, and dissociative presentations.
• Framework parallels alcohol withdrawal management, where empiric benzodiazepine treatment is already standard despite diagnostic ambiguity.

Action Items

• Recognize waxing-and-waning mutism, staring, and posturing as triggers for empiric trial.
• Establish lorazepam challenge protocols accessible across inpatient settings.
• Train teams on catatonia rating scales to reduce interrater variability.
• Review institutional ECT availability and referral pathways for refractory cases.